Compare Stocks

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

StarTek, Inc., a business process outsourcing company, provides customer experience, digital transformation, and technology services in various markets. The company primarily offers customer engagement, omnichannel engagement, social media, customer intelligence analytics, work from home, and back-office services under the Startek and Aegis brands. It also offers Startek cloud, a hybrid omni-cloud platform integrated with artificial intelligence capabilities, which enables agents to work in remote and home-based roles for increased business agility and continuity. The company serves telecom, e-commerce and consumer, financial and business services, cable and media, travel and hospitality, technology, education and healthcare, energy, and other industries in the Americas, India, Sri Lanka, Malaysia, South Africa, Australia, and internationally. StarTek, Inc. was founded in 1987 and is headquartered in Denver, Colorado.